依达拉奉联合醒脑静对急性脑出血患者GCS及NIHSS评分的影响

目的 研究依达拉奉联合醒脑静对急性脑出血(ACH)的治疗疗效及对患者神经功能的影响.方法 将2013年9月至2016年9月在榆林市第一医院住院治疗的ACH患者178例纳入研究,依照随机数表法分为观察组和对照组各89例.两组患者均给予常规治疗,对照组另给予依达拉奉静滴,观察组基于对照组的用药方案另增加醒脑静.比较两组患者治疗2周后的疗效、治疗前后GCS评分及神经功能缺损NIHSS评分、血肿量及C反应蛋白(CRP)水平以及不良反应.结果 观察组患者的治疗总有效率为97.75%,明显高于对照组的89.89%,差异有统计学意义(P<0.05);治疗后观察组患者的GCS评分为(15.62±6.57)分,明显高于对照组的(12.45±4.38)分,NIHSS评分为(10.15±3.06)分,明显低于对照组的(17.52±6.35)分,差异均有统计学意义(P<0.05);治疗后观察组的血肿量和CRP水平分别为(3.47±0.82)mL和(6.24±1.13)ng/L,均明显低于对照组的(8.52±1.26)mL和(12.68±1.59)ng/L,差异均有统计学意义(P<0.05);观察组不良反应总发生率为2.25%,与对照组的6.74%比较,差异无统计学意义(P>0.05).结论 依达拉奉与醒脑静联合治疗ACH患者可有效提升疗效,改善神经功能,安全性较好,值得临床推广.

Effect of edaravone combined with Xingnaojing injection on GCS and NIHSS score in patients with acute cerebral hemorrhage

Objective To study the effect of edaravone combined with Xingnaojing injection on clinical effica-cy and neurologic function in patients with acute cerebral hemorrhage. Methods From September 2013 to September 2016, 178 patients with acute cerebral hemorrhage who were treated in Yulin First Hospital were selected and randomly divided into the observation group (n=89) and the control group (n=89) according to random number table. Based on con-ventional treatment, the control group was given intravenous infusion of edaravone, and the observation group was given edaravone combined with Xingnaojing injection. The clinical efficacy after 2 weeks of treatment, the Glasgow Coma Scale (GCS) and National Institutes of Health Stroke Scale (NIHSS), hematoma volume, and C-reactive protein (CRP) level before and after treatment were compared between the two groups, as well as adverse reactions. Results The total effective rate of the observation group was 97.75%, which was significantly higher than 89.89%in the control group (P<0.05). After treatment, the GCS score, NIHSS score, hematoma volume, CRP level were (15.62 ± 6.57), (10.15 ± 3.06), (3.47±0.82) mL, (6.24±1.13) ng/L in the observation group, respectively, as compared with (12.45±4.38), (17.52±6.35), (8.52±1.26) mL, (12.68±1.59) ng/L in control group (P<0.05). The total incidence of adverse reactions showed no statis-tically significant difference between the two groups, 2.25%vs 6.74%, P>0.05. Conclusion Edaravone combined with Xingnaojing injection in the treatment of patients with acute cerebral hemorrhage can effectively improve the curative ef-fect and neurological function, with good safety, which is worthy of promotion.